Lakefront Biotherapeutics NV current report, Q1 FY2022

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of March 2022, with a specific reporting date of March 28, 2022. The filing serves to incorporate by reference a press release (Exhibit 99.1) issued on that date. The registrant is a foreign private issuer based in Mechelen, Belgium, filing under Form 20-F.

Financial Metrics

The provided filing text does not contain specific financial data. It is a procedural filing referencing an external press release. Consequently, no values are available for revenue, profit, cash flow, margins, debt, or liquidity within this document.

Material Changes

The filing text does not detail specific material changes or comparative period analysis. It solely confirms the issuance of a press release on March 28, 2022, which is attached as Exhibit 99.1 but not reproduced in the provided text.

Guidance, Outlook, and Risks

Management commentary, guidance, outlook, risks, contingencies, and unusual items are not present in the provided text. These details would be contained within the referenced Exhibit 99.1 press release, the content of which is not included in the input.

Key Facts for Investor Verification

  • Company Identity: Verify that the filing pertains to Galapagos NV, not Lakefront Biotherapeutics NV.
  • Source of Information: The substantive news is located in Exhibit 99.1 (Press Release dated March 28, 2022), which is not included in the provided text.
  • Registration Statements: The press release is incorporated by reference into multiple Registration Statements on Forms F-3 and S-8.
  • Financial Data: No financial metrics are disclosed in this specific Form 6-K text; investors must consult the full press release or other financial reports for quantitative data.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.